Loading
NASDAQHealthcareMedical - Devices
Latest quote
$5.68
−$0.40 · -6.58%
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Previous close
$5.68
−$0.40 · -6.58%
Pre-market
$6.75
+$1.07 · +18.84%
Oct 8, 4:12 AM ET
Regular session · ET · Market data may be delayed.
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Day range
Current $5.68
52-week range
Current $5.68
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
66
Undervalued
Sentiment
43
Mixed
Risk
45
Elevated Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Day range
Current $5.68
52-week range
Current $5.68
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.38M USD | 10.17M USD | 7.2M USD | 6.68M USD | 6.87M USD |
| Cost of goods sold | 4.79M USD | 3.47M USD | 2.82M USD | 3.66M USD | 3.92M USD |
| Gross profit | 11.59M USD | 6.7M USD | 4.38M USD | 3.02M USD | 2.95M USD |
| Research and development | 20.96M USD | 16.15M USD | 14.38M USD | 14.69M USD | 15.28M USD |
| Selling, general, and administrative | 32.61M USD | 22.02M USD | 18.62M USD | 17.93M USD | 17.97M USD |
| Operating expenses | 53.57M USD | 38.17M USD | 33M USD | 35.15M USD | 33.24M USD |
| Interest income | 1.09M USD | 1.37M USD | 1.64M USD | 1.05M USD | 203.2K USD |
| Interest expense | — | — | 770K USD | 167.11K USD | 66.41K USD |
| Depreciation and amortization | 569.8K USD | 936K USD | 929K USD | 1.6M USD | 1.88M USD |
| Operating income | −41.98M USD | −31.47M USD | −28.62M USD | −32.13M USD | −30.29M USD |
| Net income | −43.32M USD | −26.48M USD | −28.57M USD | −28.67M USD | −30.7M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.00
93.66% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 16, 2019 | 1:10 | — | — |
Effective Oct 16, 2019
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Invesco NASDAQ Future Gen 200 ETFQQQS
Dimensional - International Core Equity 2 ETFDFIC
State Street SPDR Portfolio Europe ETFSPEUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
